Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Canakinumab by Novartis for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
Canakinumab is under clinical development by Novartis and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData,...
Canakinumab by Novartis for Myelodysplastic Syndrome: Likelihood of Approval
Canakinumab is under clinical development by Novartis and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II...
Canakinumab by Novartis for Metastatic Melanoma: Likelihood of Approval
Canakinumab is under clinical development by Novartis and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...